As seen in FiercePharmaMarketing’s “How to Speak on Social Media? Finally, the FDA Offers More Specific Clues”
FiercePharmaMarketing reports that the Food and Drug Administration (FDA) recently issued draft guidance for pharmaceutical companies looking to utilize social media for marketing purposes. The two sets of rules address how the risks-and-benefits disclosures that must be included in all promotional materials should be published on social media that limits the length of such messages, as well as how and when pharmaceutical companies should address misinformation posted by third parties.
According to Kaye Scholer Life Sciences Partner Lori Leskin, "The two different guidance drafts reaffirm the FDA's intent that information about potential risks be included along with the potential benefits, but also recognizes the realities of today's social media platforms." She added, "Up until now, pharmaceutical companies have not engaged with the public on social media, in part due to the uncertainty of the regulatory atmosphere governing their participation."
Also of Interest
- NLJ Names Shores as Antitrust Trailblazer September 27, 2016 • Recognitions
- Shape of Things to Come: Protecting Product Configuration and Packaging Design September 26, 2016 • Articles
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles
- Druckenbrodt Quoted in Bloomberg on Volkswagen Dieselgate September 14, 2016 • Media Mentions
- Arbisser Featured in The Recorder and Law360... September 7, 2016 • Media Mentions
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- ILS and Zinsser Analytic Shareholders Sell to Gardner Denver Medical September 2, 2016 • Client Successes
- Kaye Scholer Secures Dismissal of Merger-Related Class Action Against Baltic Trading September 1, 2016 • Client Successes
- Kaye Scholer Advises Veracen on Merger of Equals with Turner Investments August 31, 2016 • Client Successes